Expression profile of tyrosine kinases in breast cancer

Funda Meric, Wei Ping Lee, Aysegul Sahin, Haixia Zhang, Hsing Jien Kung, Mien Chie Hung

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.

Original languageEnglish
Pages (from-to)361-367
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number2
Publication statusPublished - Jan 1 2002
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Breast Neoplasms
Cell Line
Reverse Transcription
Receptor, Fibroblast Growth Factor, Type 4
Janus Kinase 1
Polymerase Chain Reaction
Growth Factor Receptors
Oncogene Proteins
Epidermal Growth Factor Receptor
Digestion
Catalytic Domain
Cell Cycle
Breast
Phosphotransferases
Epithelial Cells
RNA
Enzymes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Meric, F., Lee, W. P., Sahin, A., Zhang, H., Kung, H. J., & Hung, M. C. (2002). Expression profile of tyrosine kinases in breast cancer. Clinical Cancer Research, 8(2), 361-367.

Expression profile of tyrosine kinases in breast cancer. / Meric, Funda; Lee, Wei Ping; Sahin, Aysegul; Zhang, Haixia; Kung, Hsing Jien; Hung, Mien Chie.

In: Clinical Cancer Research, Vol. 8, No. 2, 01.01.2002, p. 361-367.

Research output: Contribution to journalArticle

Meric, F, Lee, WP, Sahin, A, Zhang, H, Kung, HJ & Hung, MC 2002, 'Expression profile of tyrosine kinases in breast cancer', Clinical Cancer Research, vol. 8, no. 2, pp. 361-367.
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clinical Cancer Research. 2002 Jan 1;8(2):361-367.
Meric, Funda ; Lee, Wei Ping ; Sahin, Aysegul ; Zhang, Haixia ; Kung, Hsing Jien ; Hung, Mien Chie. / Expression profile of tyrosine kinases in breast cancer. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 2. pp. 361-367.
@article{81ec97e54f414011bf6ff57f3e7a2383,
title = "Expression profile of tyrosine kinases in breast cancer",
abstract = "The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.",
author = "Funda Meric and Lee, {Wei Ping} and Aysegul Sahin and Haixia Zhang and Kung, {Hsing Jien} and Hung, {Mien Chie}",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "361--367",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Expression profile of tyrosine kinases in breast cancer

AU - Meric, Funda

AU - Lee, Wei Ping

AU - Sahin, Aysegul

AU - Zhang, Haixia

AU - Kung, Hsing Jien

AU - Hung, Mien Chie

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.

AB - The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins. Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior. Thus, TKs are being actively pursued as therapeutic targets. The purpose of this study was to determine the expression pattern of TKs in breast cancer. Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were determined by digestion with a panel of restriction enzymes. Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines. The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines. Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells. Several kinases were differentially expressed among the cell lines. Similar TK profiles were found using RNA from human breast tumors. We conclude that there is significant variability in the TK expression pattern of breast cancers. This variability should be considered when selecting TK inhibitors to treat patients.

UR - http://www.scopus.com/inward/record.url?scp=0036184567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036184567&partnerID=8YFLogxK

M3 - Article

C2 - 11839650

AN - SCOPUS:0036184567

VL - 8

SP - 361

EP - 367

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -